Tiantan Bio (600161.SH) subsidiary company receives clinical trial summary report.

CapitalEye Financial News APP: Tiens Group (600161.SH) has announced that recently, the "Human Prothrombin Complex" developed by its subsidiary, Guizhou Biopharmaceutical Co., Ltd. (referred to as "Tiens Guizhou"), has completed Phase III clinical trials and obtained the clinical trial summary report.